| Bioactivity | GSK329 is a potent and selective diarylurea inhibitor of the cardiac-specific kinase TNNI3K. GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury[1]. |
| Target | TNNI3K |
| Name | GSK329 |
| CAS | 1268490-12-5 |
| Formula | C19H14Cl2F3N5O2 |
| Molar Mass | 472.25 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Patterson JR, et, al. Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-Raf. J Med Chem. 2021 Nov 11;64(21):15651-15670. |
GSK329
CAS: 1268490-12-5 F: C19H14Cl2F3N5O2 W: 472.25
GSK329 is a potent and selective diarylurea inhibitor of the cardiac-specific kinase TNNI3K. GSK329 exhibits positive ca
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.